Add time:08/12/2019         Source:sciencedirect.com

BackgroundInflammatory bowel diseases (IBD) are a group of chronic and recurrent gastrointestinal disorders that are difficult to control. Recently, a new IBD therapy based on the targeting of the endogenous opioid system has been proposed. Consequently, due to the fact that endogenous enkephalins have an anti-inflammatory effect, we aimed at investigating the degradation of serum enkephalin (Met- and Leu-enkephalin) in patients with IBD.

We also recommend Trading Suppliers and Manufacturers of enkephalin, Met(2)-ProNH2(5)(N(1.5)-glucopyranosyl) (cas 113282-21-6). Pls Click Website Link as below: cas 113282-21-6 suppliers